Development of peripheral opioid antagonists: new insights into opioid effects

J Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - Elsevier
The recent approval by the US Food and Drug Administration of 2 medications—
methylnaltrexone and alvimopan—introduces a new class of therapeutic entities to …
被引用次数：112 相关文章

Development of peripheral opioid antagonists: new insights into opioid effects.

J Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - go.gale.com
The recent approval by the US Food and Drug Administration of 2 medication--
methylnaltrexone and alvimopan--introduces a new class of therapeutic entities of clinicians …

Development of Peripheral Opioid Antagonists: New Insights Into Opioid Effects

J Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - mayoclinicproceedings.org
The recent approval by the US Food and Drug Administration of 2 medications—
methylnaltrexone and alvimopan—introduces a new class of therapeutic entities to …

Development of Peripheral Opioid Antagonists: New Insights Into Opioid Effects

MD Jonathan Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - search.proquest.com
The recent approval by the US Food and Drug Administration of 2 medications--
methylnaltrexone and alvimopan--introduces a new class of therapeutic entities to clinicians …

Development of Peripheral Opioid Antagonists: New Insights Into Opioid Effects

J Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - infona.pl
The recent approval by the US Food and Drug Administration of 2 medications—
methylnaltrexone and alvimopan—introduces a new class of therapeutic entities to …

Development of peripheral opioid antagonists' new insights into opioid effects

J Moss, CE Rosow - Mayo Clinic proceedings, 2008 - pubmed.ncbi.nlm.nih.gov
The recent approval by the US Food and Drug Administration of 2 medications--
methylnaltrexone and alvimopan--introduces a new class of therapeutic entities to clinicians …

Development of Peripheral Opioid Antagonists: New Insights Into Opioid Effects

J Moss, CE Rosow - Mayo Clinic Proceedings, 2008 - infona.pl
The recent approval by the US Food and Drug Administration of 2 medications—
methylnaltrexone and alvimopan—introduces a new class of therapeutic entities to …